AllSci News
Cbio advances novoleucel T-cell therapy into first-in-human trial for recurrent cervical cancer
Copenhagen-based Cbio A/S has received European regulatory clearance to initiate a first-in-human Phase I/IIa clinical trial of novoleucel, a T-cell therapy...
PepGen faces FDA partial clinical hold on PGN-EDODM1 trial for myotonic dystrophy type 1
PepGen Inc. (Nasdaq: PEPG) announced that the U.S. Food and Drug Administration has placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 multiple...
VST BIO Corporation Closes Series A Financing With $45M Total Investment to Advance Stroke Therapy
VST BIO Corporation, a San Diego-headquartered biotechnology company developing therapeutics for acute ischemic stroke, has closed a Series A financing...
GlycoNex and Nippon Kayaku partner to co-develop tumor-activated ADC targeting solid tumors
GlycoNex Inc., a clinical-stage biotechnology company based in New Taipei City, Taiwan, and Nippon Kayaku Co., Ltd., a Tokyo-based pharmaceutical and...
Eli Lilly's lebrikizumab delivers positive Phase 3 results in pediatric atopic dermatitis trial
Eli Lilly announced positive Phase 3 results for EBGLYSS (lebrikizumab-lbkz) in pediatric patients aged six months to 18 years with moderate-to-severe...
FDA Approves Cosentyx for Pediatric Moderate-to-Severe Hidradenitis Suppurativa in Patients Aged 12 and Older
The US FDA has approved Cosentyx (secukinumab) for the treatment of pediatric patients aged 12 years and older with moderate to severe hidradenitis...
Insmed's Arikayce meets primary endpoint in Phase IIIb ENCORE study for MAC lung disease
Insmed (Nasdaq: INSM) reported that its Phase IIIb ENCORE study of Arikayce (amikacin liposome inhalation suspension) met its primary endpoint and all...
Dianthus Therapeutics raises USD 625m in upsized underwritten public offering
Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company based in New York City and Waltham, Massachusetts, announced the pricing...
Bristol Myers Squibb's mezigdomide shows positive phase 3 results in relapsed multiple myeloma
Bristol Myers Squibb announced positive interim results from the SUCCESSOR-2 study, a Phase 3 trial evaluating oral mezigdomide in combination with...
GSK licences linerixibat worldwide rights to Alfasigma in deal worth up to USD 690m.
GSK plc (LSE/NYSE: GSK), headquartered in London, and Bologna-based Alfasigma S.p.A. have entered into a licence agreement under which Alfasigma will...
FDA Aligns on Accelerated Approval Pathway for NovaBridge's Givastomig in Gastroesophageal Cancer
Clarification: This article concerns a regulatory pathway alignment, not a formal drug approval. The US FDA has not approved givastomig. The source material...
Insilico Medicine and Tenacia Biotechnology expand AI-driven CNS collaboration worth up to USD 94.75m
Insilico Medicine and Tenacia Biotechnology have expanded their AI-driven CNS collaboration, adding a second discovery-stage program targeting an...
FDA Approves Loargys by Immedica Pharma for Hyperargininemia in Arginase 1 Deficiency Patients
The US FDA has granted accelerated approval to Loargys (pegzilarginase-nbln) for the treatment of hyperargininemia in adult and pediatric patients aged two...
Novo Nordisk's UBT251 shows strong HbA1c and weight reductions in type 2 diabetes Phase II trial
Novo Nordisk and The United Laboratories International Holdings Limited reported topline results from a Phase II trial of UBT251, a once-weekly injectable...
SK Bioscience Secures USD 3M RIGHT Foundation Grant to Advance RSV Antibody Development
SK bioscience, a vaccine and biotechnology company headquartered in Incheon, South Korea, has secured KRW 4 billion (approximately USD 3.0 million) from the...
The AllSci Brief
Systematic R&D and deal news. Daily.